#Europe

Gilead Sciences’ “Zeroing In” program helps 116 grantees boost HIV innovation, education and outreach in marginalized communities.

IAPAC president and CEO José M. Zuniga, PhD, MPH, reflects on the current humanitarian crisis in Ukraine and how you can help.

Researchers found that Truvada as pre-exposure prophylaxis greatly reduced HIV cases in both people on PrEP and those not on it.

A study looked at the fat composition of people who switched their antiretrovirals to include an integrase inhibitor.

Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

Disruptions in access to antiretroviral treatment due to the COVID-19 pandemic could lead to a major setback in combating HIV.

Antiretrovirals likely drive up rates, both directly and by helping people live long enough to develop high blood pressure.

Courtesy of the Scottish police, Amsterdam and four cities in Ireland

The famed London sexual health clinic 56 Dean Street revealed that post-exposure prophylaxis prescriptions declined dramatically.

A recent Swedish study defined a low-level detectable viral load as between 50 and 999.

Studies have found that weight gain is common after people with HIV begin an antiretroviral in this class.

This finding, which is in keeping with initial studies out of China and Italy, is preliminary as the CDC continues to gather data.

A recent small study examined pairings of antiretrovirals and statins or blood pressure medications.

A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.

In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.